Mohamed K. Mohamed, MD
Pembrolizumab (Keytruda) has emerged as a reliable frontline treatment option for patients with metastatic non–small cell lung cancer (NSCLC), but thoracic oncologists need to be aware of potentially severe immune-related adverse events (irAEs), said Mohamed K. Mohamed, MD.
A trio of positive phase III studies—KEYNOTE-024, KEYNOTE-189, and KEYNOTE-407—has led to recent FDA approvals for pembrolizumab in multiple frontline indications. Despite the encouraging survival data and response rates observed in these studies, these irAEs associated with the PD-1 inhibitor need to be considered, said Mohamed, a hematologist/oncologist at Cone Health Medical Group.
“In these trials, the AEs with pembrolizumab were comparable with what was seen in the control arms, but the handling of these toxicities is what makes them unique and challenging,” Mohamed said during a presentation at the 2018 New York Lung Cancers Symposium.
... to read the full story